KR880007732A - B형 간염에 대한 백신의 제조방법 및 이 방법으로 수득된 백신 - Google Patents
B형 간염에 대한 백신의 제조방법 및 이 방법으로 수득된 백신 Download PDFInfo
- Publication number
- KR880007732A KR880007732A KR870014091A KR870014091A KR880007732A KR 880007732 A KR880007732 A KR 880007732A KR 870014091 A KR870014091 A KR 870014091A KR 870014091 A KR870014091 A KR 870014091A KR 880007732 A KR880007732 A KR 880007732A
- Authority
- KR
- South Korea
- Prior art keywords
- particles
- centrifugation
- carried out
- hbsag
- vaccine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 229960005486 vaccine Drugs 0.000 title claims 3
- 208000002672 hepatitis B Diseases 0.000 title claims 2
- 239000002245 particle Substances 0.000 claims 6
- 238000005119 centrifugation Methods 0.000 claims 5
- 230000000890 antigenic effect Effects 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 238000001556 precipitation Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 3
- 239000008118 PEG 6000 Substances 0.000 claims 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 108091005461 Nucleic proteins Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 238000005349 anion exchange Methods 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 230000003196 chaotropic effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 238000005188 flotation Methods 0.000 claims 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- HBsAg 유전자를 운반하는 플라스미드에 의해 감염된 CHO세포의 배양액으로부터 형질 발현에 의해 배양배지에 항원성 표면 입자를 방출시킴으로써 B형 간염의 표면 항원성 입자를 제조하는데 있어서, 적어도 하나의 배양액, 특히 낮은 동물 혈청 함량을 갖는 배지로부터 상층 배양 배지를 회수하고, 상층액을 멸균 여과하고, 상층액을 농축하고, 농축물을 헤비 DNA 종류, 레트로 비루스 입자 및 단백질을 침전시키는 조건하에 비-분해 침전제에 의해 침전시키고, 새로운 농축을 수행하고, 레트로비루스 입자를 위해 비-카오트로픽 밀도경사에서 레이트 존 원심분리를 수행하여 그의 크기 및 밀도에 따라 HBsAg입자로부터 이들을 분리하고, 부상형의 이소피크닉 존 원심분리를 수행하여 라이트 및 헤비 핵산 및 단백질을 제거하고, 음이온 교환매질에서 크로마토그래피를 수행하여 나머지 미량의 핵산 및 나머지 비-HBsAg 단백질을 흡착시킴을 특징으로 하는 신규의 재조합 B형 간염 백신의 제조방법.
- 제1항에 있어서, 폴리에틸렌글리콜, 특히 PEG 6000으로 침전을 수행함을 특징으로 하는 방법.
- 제2항에 있어서, 1차 침전을 5%의 PEG농도로 수행함을 특징으로 하는 방법.
- 제1~3항 중 어느 한 항에 있어서, 새로운 농축을 HBsAg 항원성 입자를 침전시키고, 그 후 침전물을 소량으로 재응해시키는 비 분해 침전제에 의해 수행함을 특징으로 하는 방법.
- 제4항에 있어서, 이 침전을 PEG, 특히 9.5% PEG6000으로 수행함을 특징으로 하는 방법.
- 제1~5항 중 어느 한 항에 있어서, 레이트 존 원심 분리를 슈크로오즈 경사에서 수행함을 특징으로 하는 방법.
- 제6항에 있어서, 원심 분리를 K-2-일렉트로뉴클레오닉스 로우터에서 수행함을 특징으로 하는 방법.
- 제6 및 7항 중 어느 한 항에 있어서, 25% 이하의 슈크로오즈 비율을 갖는 분획을 선택하고, 다른 분획은 제거함을 특징으로 하는 방법.
- 제1~8항 중 어느 한 항에 있어서, 존 부상형 원심 분리를 KBr 경사에서 수행함을 특징으로 하는 방법.
- 제9항에 있어서, 어느 한 항에 있어서, 밀도 피크 1.22~1.23의 분획을 수거함을 특징으로 하는 방법.
- 제1~6항 중 어느 한 항에 있어서, 크로마토그래피를 DE52 셀룰로오즈에 수행함을 특징으로 하는 방법.
- 높은 S 및 특히 pre-S 면역원성을 갖는, 제1~11항 중 어느 한 항의 방법에 의해 수득된 백신.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8617265A FR2608052B1 (fr) | 1986-12-10 | 1986-12-10 | Procede de preparation d'un vaccin contre l'hepatite b et vaccin obtenu |
| FR86-17265 | 1986-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR880007732A true KR880007732A (ko) | 1988-08-29 |
Family
ID=9341743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR870014091A KR880007732A (ko) | 1986-12-10 | 1987-12-10 | B형 간염에 대한 백신의 제조방법 및 이 방법으로 수득된 백신 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0273811B1 (ko) |
| JP (1) | JPS63215639A (ko) |
| KR (1) | KR880007732A (ko) |
| AT (1) | ATE109353T1 (ko) |
| CA (1) | CA1306689C (ko) |
| DE (1) | DE3750330T2 (ko) |
| DK (1) | DK645687A (ko) |
| FR (1) | FR2608052B1 (ko) |
| IL (1) | IL84729A (ko) |
| NO (1) | NO171147C (ko) |
| PT (1) | PT86321B (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073604A (zh) * | 1991-12-01 | 1993-06-30 | 高真南 | 制备高免疫原性乙型肝炎疫苗的方法 |
| AU3269793A (en) * | 1991-12-27 | 1993-07-28 | Gensci Limited | Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1356413A (en) * | 1971-09-09 | 1974-06-12 | Pfizer Ltd | Method of obtaining purified australia antigen from blood serum |
| US4088748A (en) * | 1976-11-02 | 1978-05-09 | Merck & Co., Inc. | Hepatitis B surface antigen |
| US4162192A (en) * | 1978-09-28 | 1979-07-24 | Juridical Foundation | Method for purification of HBs antigen |
| FR2560890B1 (fr) * | 1984-03-07 | 1987-10-16 | Grp Genie Genetique | Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention |
| US4624918A (en) * | 1984-07-09 | 1986-11-25 | Genentech, Inc. | Purification process for hepatitis surface antigen and product thereof |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
-
1986
- 1986-12-10 FR FR8617265A patent/FR2608052B1/fr not_active Expired - Lifetime
-
1987
- 1987-12-03 AT AT87402743T patent/ATE109353T1/de not_active IP Right Cessation
- 1987-12-03 DE DE3750330T patent/DE3750330T2/de not_active Expired - Lifetime
- 1987-12-03 EP EP87402743A patent/EP0273811B1/fr not_active Expired - Lifetime
- 1987-12-07 IL IL84729A patent/IL84729A/xx not_active IP Right Cessation
- 1987-12-09 PT PT86321A patent/PT86321B/pt not_active IP Right Cessation
- 1987-12-09 NO NO875142A patent/NO171147C/no unknown
- 1987-12-09 DK DK645687A patent/DK645687A/da not_active Application Discontinuation
- 1987-12-09 CA CA000553878A patent/CA1306689C/en not_active Expired - Lifetime
- 1987-12-10 JP JP62313100A patent/JPS63215639A/ja active Pending
- 1987-12-10 KR KR870014091A patent/KR880007732A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2608052A1 (fr) | 1988-06-17 |
| PT86321A (fr) | 1988-01-01 |
| IL84729A (en) | 1993-02-21 |
| DK645687D0 (da) | 1987-12-09 |
| DE3750330D1 (de) | 1994-09-08 |
| ATE109353T1 (de) | 1994-08-15 |
| NO171147C (no) | 1993-02-03 |
| DE3750330T2 (de) | 1994-11-17 |
| NO875142D0 (no) | 1987-12-09 |
| EP0273811B1 (fr) | 1994-08-03 |
| PT86321B (pt) | 1990-11-07 |
| EP0273811A2 (fr) | 1988-07-06 |
| JPS63215639A (ja) | 1988-09-08 |
| EP0273811A3 (en) | 1988-08-03 |
| NO171147B (no) | 1992-10-26 |
| IL84729A0 (en) | 1988-05-31 |
| NO875142L (no) | 1988-06-13 |
| CA1306689C (en) | 1992-08-25 |
| FR2608052B1 (fr) | 1990-04-13 |
| DK645687A (da) | 1988-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kressmann et al. | Transcription of xenopus tDNAmet1 and sea urchin histone DNA injected into the Xenopus oocyte nucleus | |
| EP0442026B1 (en) | Method to extract and purify human genomic DNA | |
| Tytell et al. | Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). | |
| Maizel Jr et al. | The polypeptides of adenovirus: I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12 | |
| Northway et al. | Differentiation of antinuclear antibodies giving speckled staining patterns in immunofluorescence | |
| Viñuela et al. | Synthesis of Virus‐Specific Proteins in Escherichia coli Infected with the RNA Bacteriophage MS2 1 | |
| Lukanidin et al. | Structure and function of informofers | |
| Nevins | [70] Definition and mapping of adenovirus 2 nuclear transcription | |
| Horwitz | Bidirectional replication of adenovirus type 2 DNA | |
| Menissier et al. | Free cauliflower mosaic virus supercoiled DNA in infected plants | |
| Vance et al. | Translation of soybean mosaic virus RNA in vitro: evidence of protein processing | |
| Somogyi et al. | Virus-specific RNA synthesis in cells infected by infectious pancreatic necrosis virus | |
| Coplin et al. | Intermediates in the biosynthesis of double-stranded ribonucleic acids of bacteriophage phi 6. | |
| Doerfler et al. | Intracellular Forms of Adenovirus Deoxyribonucleic Acid I. Evidence for a Deoxyribonucleic Acid-Protein Complex in Baby Hamster Kidney Cells Infected with Adenovirus Type 12 | |
| JPH0112760B2 (ko) | ||
| Harshey et al. | Infecting bacteriophage Mu DNA forms a circular DNA-protein complex | |
| Macleod et al. | Experimental evidence of a relationship between turnip yellow mosaic virus and wild cucumber mosaic virus | |
| Carter et al. | The recognition of viral RNA by mammalian ribosomes: an effect of interferon | |
| Spector et al. | Polyadenylic acid on poliovirus RNA: IV. Poly (U) in replicative intermediate and double-stranded RNA | |
| KR880007732A (ko) | B형 간염에 대한 백신의 제조방법 및 이 방법으로 수득된 백신 | |
| Riedel et al. | Circular single stranded phage M13-DNA as a template for DNA synthesis in protein extracts from Xenopus laevis eggs: evidence for a eukaryotic DNA priming activity | |
| McMaster et al. | Rapid purification of covalently closed circular DNAs of bacterial plasmids and animal tumor viruses | |
| Graves et al. | Immunochemical studies of foot-and-mouth disease: II. Characterization of RNA-free viruslike particles | |
| Smith et al. | Rapid purification of 70 S RNA from media of cells producing RNA tumor viruses | |
| Rosenberg et al. | Isolation and subunit structure of polycytidylate-dependent RNA polymerase of encephalomyocarditis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |